Ralph Hauke, MD
Hematology & Oncology · Omaha, NENPI 1578511283
Payments from drug & device makers
Across 1,774 payments — averaging $6811.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$4.9M
- Novartis$2.5M
- E.r. Squibb & Sons, L.L.C.$1.3M
- Exelixis Inc.$408K
- AVEO Pharmaceuticals, Inc.$387K
- Astrazeneca AB$382K
- plus $2.2M from 31 others
Across 4 payments — averaging $1368.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$4K
- Eli Lilly$706
- Novartis Pharma AG$609
What the payments were for
- Consulting fees$7,50886%
- Travel & lodging$4105%
- Food & beverage$7298%
- Education$430%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 243 | $4,930,879 |
| Novartis | 30 | $2,522,848 |
| E.r. Squibb & Sons, L.L.C. | 83 | $1,271,765 |
| Exelixis Inc. | 149 | $408,127 |
| AVEO Pharmaceuticals, Inc. | 193 | $386,858 |
| Astrazeneca AB | 4 | $382,088 |
| Macrogenics, Inc. | 61 | $370,898 |
| AbbVie | 167 | $299,421 |
| Astellas Pharma Global Development | 74 | $296,654 |
| Pfizer | 28 | $293,397 |
| Biontech SE | 78 | $254,614 |
| Eisai Inc. | 371 | $166,360 |
| Janssen Research & Development, LLC | 152 | $158,166 |
| AstraZeneca | 2 | $58,699 |
| Dynavax Technologies Corporation | 5 | $38,396 |
| Hoffmann-la Roche Limited | 8 | $35,250 |
| Bayer | 8 | $34,894 |
| Pharmacyclics LLC, An Abbvie Company | 13 | $27,041 |
| Array Biopharma Inc | 28 | $23,907 |
| Gilead | 11 | $22,962 |
| Incyte Corporation | 39 | $18,629 |
| Orion Corporation | 1 | $16,750 |
| EMD Serono, Inc. | 1 | $14,750 |
| Tesaro, Inc. | 1 | $13,518 |
| Bausch Health US, LLC | 1 | $12,500 |
| Astellas Pharma US Inc | 5 | $7,342 |
| Genentech, Inc. | 4 | $6,164 |
| Eli Lilly | 1 | $5,000 |
| Novocure Inc. | 2 | $3,373 |
| Immunomedics, Inc. | 1 | $1,250 |
| Janssen Scientific Affairs, LLC | 1 | $758 |
| Amgen | 1 | $596 |
| Advanced Accelerator Applications | 3 | $272 |
| Verity Pharmaceuticals Inc. | 2 | $41 |
| Dendreon Pharmaceuticals LLC | 1 | $36 |
| Sirtex Medical Inc | 1 | $15 |
| Epizyme, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,084,230 in reported general payments places this provider in the 95th percentile of 73 hematology & oncology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CabometyxCabozantinib S-Malate | 33 | $778,289 |
| XtandiEnzalutamide | 49 | $710,247 |
| OnuregAzacitidine | 13 | $307,559 |
| ImbruvicaIbrutinib | 13 | $212,243 |
| Abiraterone Acetate | 153 | $208,701 |
| NubeqaDarolutamide | 12 | $164,214 |
| ErleadaApalutamide | 11 | $147,961 |
| BrukinsaZanubrutinib | 11 | $126,582 |
| InlytaAxitinib | 13 | $98,816 |
| VenclextaVenetoclax | 13 | $82,353 |
| OrgovyxRelugolix | 14 | $37,655 |
| EliquisApixaban | 38 | $27,084 |
| XareltoRivaroxaban | 24 | $19,210 |
| Hydrocortisone | 24 | $1,835 |
| Potassium Chloride | 48 | $1,017 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Exelixis Inc.Cabometyx | $408,127 | $778,28933 claims |
| Astellas Pharma US IncXtandi | $7,342 | $710,24749 claims |
| E.r. Squibb & Sons, L.L.C.Onureg | $1,271,765 | $307,55913 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $27,041 | $212,24313 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $758 | $208,701153 claims |
| BayerNubeqa | $34,894 | $164,21412 claims |
| PfizerInlyta, Eliquis | $293,397 | $125,90151 claims |
| AbbVieVenclexta | $299,421 | $82,35313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 73 hematology & oncology providers in Nebraska.
Other hematology & oncology in Omaha
- Luke NordquistOmaha$29.3M
- Margaret BlockOmaha$8.3M
- Stefano TarantoloOmaha$3.7M
- Julie VoseOmaha$3.5M
- Robert BociekOmaha$3M
- Vijaya BhattOmaha$2.2M
- Mojtaba AkhtariOmaha$1.9M
- Mary WellsOmaha$1.6M
- Robert LangdonOmaha$1.2M
- Yungpo SuOmaha$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.